Replies to post #351666 on Amarin Corp Plc (AMRN)

[rafunrafun]

Does anyone know Hikma’s and Reddy’s relationship (if any) with Pfizer in the USA?

Are they competitors or partners or neither in sales / promotion of any product?

If they have a friendly relationship, it may be easier for them to get generics to back off and/or work out a settlement.

[Webster_iam]

Sstyles, that's what makes the most sense to me. They could have included a clause upon change of control, but if I'm HLS, that's not going to fly.
With that said, as far as the HLS contract with Pfizer, I think HLS realized (especially with COVID) they couldn't realize the potential of Vascepa without some pretty big shoes to help.

Webster

[sts66]

Section 2.1.3 does not mean AMRN had any involvement in the HLS/PFE deal - co-promotion is not the same as a sub-license, the latter is a deal where the licensee sells/distributes the physical product and retains all revenues. It's akin sub-letting an apt - if you can rent it to someone else for more than you are paying the owner you get to pocket the diff - assuming the lease doesn't prevent sub-letting, of course.. Someone posted an example of a biotech doing this a few days ago - they licensed a drug to develop from a BP for low single digit royalties if it ever got approved (prostate cancer drug), then they subsequently partnered with another BP after successful trials in which they would share profits at 50:50 plus milestone payments - the BP that gave them the initial license isn't entitled to any more than the original royalty rate.